Sage Therapeutics, National Institutes of Health, Scripps Research Institute, University of Utah neurology news

NIH's Blueprint Neurotherapeutics Network (BPN) granted Sage an award worth up to $10 million to develop a positive allosteric modulator (PAM) of GABA A receptor to treat anxiety and social deficits in patients with fragile X syndrome. The company will receive $162,500 in 2013, and funding will be reviewed semi-annually and awarded based on milestone achievements. Sage will also have access to the network's discovery, early stage and Phase I development services. Sage will retain any IP related to its research. The company could not be reached for details. ...